News

Filter

Current filters:

None

Popular Filters

8047 to 8071 of 8854 results

Celgene to drop Revlimid in CR prostate cancer following Ph III trial failure

23-11-2011

There was disappointment for blockbuster for multiple myeloma drug Revlimid (lenalidomide) when the Swiss…

BiotechnologyCelgeneOncologyPharmaceuticalResearchRevlimid

Problems identified in Canada’s drug regulatory system

23-11-2011

A report presented to the Canadian Parliament this week by John Wiersema, Interim Auditor General of…

North AmericaPharmaceuticalRegulation

EMA makes interim recommendations to deal with shortcomings at Ben Venue Labs

23-11-2011

The European Medicines Agency (EMA) is currently reviewing shortcomings in quality assurance identified…

Boehringer IngelheimEuropeMarkets & MarketingNorth AmericaPharmaceuticalRegulation

Indian HIV drugs market forecast to reach $54 million by 2014

23-11-2011

The market for HIV drugs in India is expected to reach 454 million by 2014, according to a new report…

Anti-viralsAsia-PacificGenericsMarkets & MarketingPharmaceutical

Merck & Co to pay $950 million for illegal marketing of Vioxx

23-11-2011

US pharma giant Merck & Co (NYSE: MRK) has agreed to pay $950 million to resolve criminal charges and…

FinancialLegalMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalVioxx

Pfizer to buy Excaliard, gaining rights to Ph II skin scarring product

23-11-2011

Global pharma behemoth Pfizer (NYSE: PFE) says it has entered into a definitive agreement to acquire…

DermatologicalsExcaliard PharmaIsis PharmaceuticalsMergers & AcquisitionsPfizerPharmaceutical

UCB adds to CNS portfolio with acquisition of Lectus’ key pharmaceutical assets

23-11-2011

Belgian drugmaker UCB (Euronext Brussels: UCB) has acquired the key pharmaceutical assets of closely-held,…

Lectus TherapeuticsMergers & AcquisitionsNeurologicalPharmaceuticalResearchUCB

FDA accepts NDA for Lundbeck and Otsuka’s aripiprazole depot formulation

23-11-2011

Danish CNS drug specialist Lundbeck (LUND: DC) and its new partner Japan’s Otsuka Pharmaceutical…

aripiprazole depotLundbeckNeurologicalNorth AmericaOtsukaPharmaceuticalRegulation

Novartis gains NIH listing in Japan for Ilaris

23-11-2011

Swiss drug major Novartis’ (NOVN: VX) Ilaris (canakinumab), a treatment for cryopyrin-associated…

Anti-Arthritics/RheumaticsAsia-PacificIlarisNovartisPharmaceuticalPricingRare diseases

Andromeda’s type 1 diabetes candidate DiaPep277 meets Ph III primary endpoint

22-11-2011

Israel-based Andromeda Biotech, a subsidiary of Clal Biotechnology Industries (TASE: CBI.TA), says initial…

AndromedaBiotechnologyClal BiotechnologyDiabetesDiaPep277ResearchTeva Pharmaceutical Industries

Promotions at Par Pharma as firm grows with acquisitions

22-11-2011

US generics drugmaker Par Pharmaceutical (NYSE: PRX) has promoted Thomas Haughey to the role of president…

GenericsManagementPar Pharmaceutical

New Australian paper shows need to complete clinical trial plan

22-11-2011

A Medicines Australia paper launched at Parliament House yesterday (November 22) shows the federal government’s…

Asia-PacificPharmaceuticalResearch

Gilead expands hepatitis C R&D portfolio with $11 billion buy of Pharmasset

22-11-2011

In its biggest M&D deal to date, Gilead Sciences (Nasdaq: GILD) says it has signed a definitive agreement…

Anti-viralsBiotechnologyGilead SciencesMergers & AcquisitionsmericitabinePharmaceuticalPharmasset

Valeant to acquire Australia’s iNova for up to $946 million

22-11-2011

Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (NYSE: VRX and TSX: VRX) has signed…

BiotechnologyiNovaMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

FDA backs EUSA Pharma’s orphan leukemia drug Erwinaze

22-11-2011

UK and USA-based specialty drug firm EUSA Pharma says that the US Food and Drug Administration has approved…

ErwinazeEUSA PharmaNorth AmericaPharmaceuticalRare diseasesRegulation

Adeona Pharma and Intrexon collaborate for synthetic DNA-based PAH therapy

22-11-2011

USA-based Adeona Pharmaceuticals (NYSE Amex: AEN) and the Human Therapeutics Division of Intrexon Corp…

Adeona PharmaCardio-vascularIntrexonLicensingPharmaceuticalResearchRespiratory and Pulmonary

USA’s CMS to cover infusion costs associated with Dendreon’s Provenge

21-11-2011

Sales of Dendreon’s (Nasdaq: DNDN) new prostate cancer treatment Provenge (sipuleucel-T) have been…

BiotechnologyDendreonNorth AmericaOncologyPharmaceuticalPricingProvengeRegulation

Turkish Pharma and Health Ministry defend clinical trials record

21-11-2011

The Turkish Ministry of Health and the country’s Association of Research-Based Pharmaceutical Companies…

EuropePharmaceuticalRegulationResearch

Hepatitis C drug market in Mexico expected to double to $104 million in 2015

21-11-2011

The hepatitis C virus (HCV) market in Mexico will nearly double from $56 million in 2010 to $104 million…

Anti-viralsIncivekMarkets & MarketingMerck & CoPharmaceuticalRocheSouth AmericaVertexVictrelis

Taiwan pharmaceutical exports rise 6.2% in 3rd-qtr 2011

21-11-2011

Year-on-year exports by Taiwan's pharmaceutical industry for the third quarter of this year saw a rise…

Asia-PacificGenericsMarkets & MarketingPharmaceutical

8047 to 8071 of 8854 results

Back to top